Journal of Managed Care & Specialty Pharmacy

Papers
(The H4-Index of Journal of Managed Care & Specialty Pharmacy is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis44
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia36
What is needed to sustain comprehensive medication management? One health plan’s perspectives36
Correction30
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data23
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis19
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy19
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities18
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments17
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness16
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance14
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review14
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder14
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues13
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies13
0.090472936630249